MARKET

ENTA

ENTA

Enanta Pharmaceuticals Inc
NASDAQ
13.14
+0.17
+1.31%
After Hours: 13.14 0 0.00% 16:10 04/02 EDT
OPEN
12.66
PREV CLOSE
12.97
HIGH
13.26
LOW
12.61
VOLUME
112.82K
TURNOVER
--
52 WEEK HIGH
17.15
52 WEEK LOW
4.090
MARKET CAP
381.31M
P/E (TTM)
-4.1006
1D
5D
1M
3M
1Y
5Y
1D
Enanta Pharma To Present Data For STAT6 Inhibitor Program At IMMUNOLOGY2026TM, Annual Meeting Of AAI
Benzinga · 5d ago
Enanta to present preclinical data on oral STAT6 inhibitor EPS-3903 at IMMUNOLOGY2026
Reuters · 5d ago
Weekly Report: what happened at ENTA last week (0323-0327)?
Weekly Report · 5d ago
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
Barchart · 5d ago
Enanta Advances Federal Circuit Appeal in Paxlovid Patent Case
TipRanks · 03/26 12:45
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 03/26 12:05
Enanta Pharmaceuticals appeal oral argument set for May 11, 2026; litigation targets Pfizer over Paxlovid patent infringement
Reuters · 03/26 12:02
Enanta initiated with a Buy at Rodman & Renshaw
TipRanks · 03/26 11:46
More
About ENTA
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.

Webull offers Enanta Pharmaceuticals Inc stock information, including NASDAQ: ENTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENTA stock methods without spending real money on the virtual paper trading platform.